# 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

> **NCT02303626** · PHASE2,PHASE3 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 110 (actual)

## Conditions studied

- Hereditary Angioedema
- HAE

## Interventions

- **DRUG:** BCX4161
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02303626
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-17
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303626, "12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02303626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*